Digestive hormones and their impact on bariatric and pharmacologic weight-loss therapies
Endocrine Reviews · 12.08.2026
DOI: 10.1210/endrev/bnag032 ↗Kurz gefasst
Fachartikel in der Zeitschrift Endocrine Reviews, online erschienen am 12.08.2026. Verfasst von Maxime Amoyel und 4 weiteren Autor:innen. Beteiligte Einrichtung: Service d'Hépato-gastro-entérologie, Hôpital Bichat-Claude-Bernard, Assistance Publique-Hôpitaux de Paris, Université Paris Cité Paris, France. Die Arbeit nennt 128 Literaturangaben.
Abstract (Originalsprache)
Obesity is a growing global health challenge associated with major cardiometabolic complications. While bariatric surgery remains the most effective treatment for severe obesity, recent advances in incretin-based pharmacotherapy, multireceptor agonists, and endoscopic bariatric procedures have substantially expanded therapeutic options. Beyond mechanical restriction, these interventions exert their effects through complex hormonal and neurophysiological mechanisms involving gut–brain signaling, gastric motility, and enteroendocrine adaptations. Gut-derived hormones, including ghrelin, glucagon-like peptide-1 (GLP-1), peptide YY, amylin, and leptin, play a central role in the regulation of hunger, satiation, and satiety by integrating nutrient sensing, vagal afferent signaling, and central hypothalamic pathways. Surgical procedures, such as laparoscopic sleeve gastrectomy and Roux-en-Y gastric bypass, induce profound and durable hormonal remodeling, whereas endoscopic sleeve gastroplasty primarily modulates gastric physiology with more modest and heterogeneous endocrine effects. Intragastric balloons induce a transient delay in gastric emptying and achieve moderate short-term weight loss, although their metabolic and weight-loss effects appear limited in durability. In parallel, GLP-1 receptor agonists and emerging multiagonist therapies reproduce several postbariatric hormonal adaptations and achieve clinically meaningful weight loss. In this review, we summarize current knowledge on digestive hormone physiology and provide an updated overview of the hormonal mechanisms underlying pharmacologic, endoscopic, and surgical bariatric interventions, highlighting their respective roles within a continuum of obesity treatment strategies.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Service d'Hépato-gastro-entérologie, Hôpital Bichat-Claude-Bernard, Assistance Publique-Hôpitaux de Paris, Université Paris Cité Paris, France.
- Inserm Université Paris Cité UMRS 1149 Centre de Recherche sur l'Inflammation Paris, France.
- Service de Nutrition, Hôpital Européen Georges Pompidou, Assistance Publique-Hôpitaux de Paris, Université Paris Cité Paris, France.
- Service de Chirurgie Digestive, Œsogastrique et Bariatrique, Hôpital Bichat-Claude-Bernard, Assistance Publique-Hôpitaux de Paris, Université Paris Cité Paris, France.
ORCID-Profile: Maxime Amoyel, Claire Carette, Tigran Poghosyan, Maude Le Gall
Zitieren
APA
Amoyel, M., Carette, C., Poghosyan, T., Le Beyec-Le Bihan, J., & Le Gall, M. (2026). Digestive hormones and their impact on bariatric and pharmacologic weight-loss therapies. Endocrine Reviews. https://doi.org/10.1210/endrev/bnag032
Vancouver
Amoyel M, Carette C, Poghosyan T, Le Beyec-Le Bihan J, Le Gall M. Digestive hormones and their impact on bariatric and pharmacologic weight-loss therapies. Endocrine Reviews. 2026. doi:10.1210/endrev/bnag032
BibTeX
@article{Amoyel2026,
author = {Amoyel, Maxime and Carette, Claire and Poghosyan, Tigran and Le Beyec-Le Bihan, Johanne and Le Gall, Maude},
title = {Digestive hormones and their impact on bariatric and pharmacologic weight-loss therapies},
journal = {Endocrine Reviews},
year = {2026},
doi = {10.1210/endrev/bnag032}
}
EUVIMED